Montreal, Canada–based green biotechnology company Aplantex raised a second round of funding, bringing the total raised to $4.6 million.
WHO: Founded in 2019, Aplantex has developed a unique green biotechnology process to produce certified high-value molecules for health, beauty, and food industries. The process consists of continuous production in a controlled environment of biomass originating from photosynthetic plant replicators. This abundant biomass is dried, and the extraction, fragmentation, and purification stages allow the separation of the specific molecules.
Aplantex’s industrial platform uses photosynthetic plant replicators to produce a variety of molecules with antioxidant, anti-inflammatory, antimicrobial, and anti-aging properties. Plant replicators have proven their ability to produce bioactive molecules in a more environmentally responsible way than agriculture, conventional biotechnology platforms, or the conventional chemical industry.
WHY: As commercialization initiatives begin, the funds raised in this recent round of funding will be used to increase the production volume of the Boucherville research and production center to meet this anticipated demand.
IN THEIR OWN WORDS: “It is with determination that the entire Aplantex team follows its game plan with discipline to become a leading supplier of high-value molecules to the pharmaceutical, cosmetics, and agri-food industries in the context of the international growth of the circular economy,” said Patrick Charest, B. SC., P.Eng., CEO of Aplantex. “We are encouraged to continue our tireless efforts by the significant support from leading private investors as well as government and institutional sources that contributed to the success of our second round of financing.”
DETAILS:
